NCT07154901 2026-02-24
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
AstraZeneca
Phase 1 Recruiting
Clinical Trials
22 trialsNCT04398745 2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1 Active not recruiting
NCT02301117 2024-09-05
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Taiho Oncology, Inc.
Phase 1 Completed
NCT03814005 2024-09-05
A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems
Takeda
Phase 1 Completed
NCT00113113 2024-08-02
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT02923947 2023-11-27
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
AstraZeneca
Phase 1 Completed
NCT04656795 2023-05-15
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
Tanabe Pharma America, Inc.
Phase 1 Completed
NCT01575925 2022-11-04
POM Renal
Celgene
Phase 1 Completed
NCT03172884 2021-04-28
Study of Copanlisib in Hepatic or Renal Impairment
Bayer
Phase 1 Completed
NCT02679131 2019-11-20
To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Acrotech Biopharma Inc.
Phase 1 Terminated
NCT00652626 2019-11-19
RENAL
Celgene
Phase 1 Completed
NCT03097016 2018-04-26
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Celgene
Phase 1 Completed
NCT00483860 2017-11-13
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
Phase 1 Completed
NCT01331941 2017-11-06
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Amgen
Phase 1 Completed
NCT01853046 2017-02-20
Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment
Bayer
Phase 1 Completed
NCT01569815 2015-10-19
Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function
Novartis
Phase 1 Completed
NCT00418366 2015-08-19
A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT02063204 2015-06-30
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
AstraZeneca
Phase 1 Completed
NCT01504165 2014-02-04
Pharmacokinetics in Subjects With Renal Impairment
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT00750620 2013-09-05
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
Astellas Pharma Inc
Phase 1 Completed
NCT01374113 2013-03-29
Safinamide Renal Impairment Trial
Newron Pharmaceuticals SPA
Phase 1 Completed